Takeda Biopharma names Annapurna Das as General Manager for India Operations
Mumbai: Takeda Biopharmaceuticals India Pvt Ltd (formerly
known as Baxalta Bioscience India Private Limited), part of a global
values-based, R&D-driven biopharmaceutical leader – has announced the
appointment of Annapurna Das as General Manager for its India operations. In
her new role, Annapurna will lead the Company in India, ensuring patient access
to its highly innovative medicines and vaccines, and advancing valuable
collaborations to contribute to the growing domestic healthcare and
pharmaceutical market.
Annapurna comes with more than 20
years of experience in the pharmaceutical and biotechnology industry across
India and Southeast Asia. Before joining Takeda, she held key leadership
positions at various multinational healthcare companies, including Miltenyi Biotec,
Sanofi, GSK, MSD, Pfizer and Organon, where she demonstrated exceptional
leadership in sales, marketing, corporate strategy and business development
across both pharma and vaccines businesses.
Commenting on her new role,
Annapurna Das said, “I am truly honoured to be entrusted with this
responsibility by Takeda. India is one of the key countries for us, given its diverse
population and the significant healthcare challenges. We are fully committed to
serving patients in India by providing them with greater access to our
innovative medicines and vaccines, ensuring they receive the best possible
care. I look forward to working closely with our stakeholders and partners to
strengthen our commitment in India while positively impacting the lives of patients
across the country.”
Welcoming her on board, Dion
Warren, Area Head of India and Southeast Asia, at Takeda said, “We
are excited to welcome Annapurna to Takeda. Her vast experience and dedication
to patient-focused solutions will fuel our continued success and growth in
India. With her strategic leadership, we strive to positively impact patients’
lives with Takeda’s innovative healthcare solutions, and partnerships to
broaden sustainable and equitable access to medicines and vaccines. Annapurna’s
alignment with Takeda’s purpose and values reinforces our commitment to
fostering a diverse and inclusive workplace, enabling us to create long-term
value for patients and society. I am excited to partner with her to build on
our strong foundation and take us to the next level of growth in India.”
A part of Takeda Pharmaceutical
Company Ltd headquartered in Japan, Takeda India specialises in
gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology
etc.
Read also: Takeda gets USFDA nod for Entyvio subcutaneous administration for Crohn’s disease
